Schrodinger Stock Soars 13.79% on Promising Cancer Data

Schrodinger's stock surged 13.79% in pre-market trading on April 11, 2025, driven by the company's recent announcements and developments.

Schrodinger, Inc. (SDGR) has unveiled promising preclinical data at the AACR 2025, highlighting the potential of its cancer inhibitors, SGR-3515 and SGR-4174. SGR-3515 has shown a promising therapeutic profile, while SGR-4174 is emerging as a potential game-changer in targeting KRAS-driven cancers, capturing significant attention in the oncology community.

Wall Street analysts have set an average one-year price target of $30.80 for Schrodinger, indicating a potential 60.25% upside from the current price. This optimistic outlook is supported by the company's groundbreaking preclinical findings and the positive reception from the oncology community.

Schrodinger's average recommendation from brokerage firms is 2.0, reflecting an "Outperform" status. This rating, along with the projected GF Value of $37.21, suggests a significant upside potential for the company's stock, driven by its innovative cancer treatments and promising preclinical data.